Tracer library / [177Lu]Lu-PEG-(DOTA)1(ACUPA)3

[177Lu]Lu-PEG-(DOTA)1(ACUPA)3

Also written as [Lu-177]PEG-(DOTA)1(ACUPA)3

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

Prostate cancer Preclinical only, no clinical indication yet

What it is

Compound class: PSMA-targeted StarPEG nanocarrier with DOTA chelator and ACUPA PSMA-targeting ligands
Target / mechanism: PSMA (prostate-specific membrane antigen) targeting via ACUPA ligand PMID 38700450
Clinical application: Imaging and therapy of prostate cancer PMID 38700450
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	SPE	91.8-99.2%	—	PEG-(DOTA)1(ACUPA)3	38700450 2024 Adv Healthc Mater StarPEG nanocarrier in water was added to a solution of 10 mM NH4OAc containing 10 vol% of ascorbic acid (20 mg/mL) and 177LuCl4 in a ratio of 0.37 MBq/μg of nanocarriers were mixed to it. - improved isolated yield (91.8-99.2%) and molar activity (14.6-15.8 MBq/nmol) were obtained for [177Lu]PEG-(DOTA)1(ACUPA)3

Need this precursor?We can point you to suppliers for [177Lu]Lu-PEG-(DOTA)1(ACUPA)3, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 38700450. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 38700450: 'PEG-(DOTA)1(ACUPA)3 (Yield 91%, 150 mg)'.